Literature DB >> 9653168

Interleukin 6 plays a key role in the development of antigen-induced arthritis.

S Ohshima1, Y Saeki, T Mima, M Sasai, K Nishioka, S Nomura, M Kopf, Y Katada, T Tanaka, M Suemura, T Kishimoto.   

Abstract

To investigate the direct role of interleukin (IL) 6 in the development of rheumatoid arthritis, IL-6-deficient (IL-6 -/-) mice were backcrossed for eight generations into C57BL/6 mice, a strain of mice with a genetic background of susceptibility for antigen-induced arthritis (AIA). Both histological and immunological comparisons were made between IL-6-deficient (IL-6 -/-) mice and wild-type (IL-6 +/+) littermates after the induction of AIA. Although all IL-6 +/+ mice developed severe arthritis, only mild arthritis was observed in IL-6 -/- mice. Safranin O staining demonstrated that articular cartilage was well preserved in IL-6 -/- mice, whereas it was destroyed completely in IL-6 +/+ mice. In addition, comparable mRNA expression for both IL-1beta and tumor necrosis factor alpha, but not for IL-6, was detected in the inflamed joints of IL-6 -/- mice, suggesting that IL-6 may play a more crucial role in cartilage destruction than either IL-1beta or tumor necrosis factor alpha. In immunological comparisons, both antigen-specific in vitro proliferative response in lymph node cells and in vivo antibody production were elicited in IL-6 -/- mice, but they were reduced to less than half of that found in IL-6 +/+ mice. Lymph node cells of IL-6 -/- mice produced many more Th2 cytokines than did IL-6 +/+ mice with either antigen-specific or nonspecific stimulation in in vitro culture. Taken together, these results indicate that IL-6 may play a key role in the development of AIA at the inductive as well as the effector phase, and the blockade of IL-6 is possibly beneficial in the treatment of rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653168      PMCID: PMC20957          DOI: 10.1073/pnas.95.14.8222

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction.

Authors:  L A Joosten; E Lubberts; P Durez; M M Helsen; M J Jacobs; M Goldman; W B van den Berg
Journal:  Arthritis Rheum       Date:  1997-02

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  IL-6/BSF2 in normal and abnormal regulation of immune responses.

Authors:  T Matsuda; S Suematsu; M Kawano; K Yoshizaki; B Tang; O Tanabe; T Nakajima; S Akira; T Hirano; T Kishimoto
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

4.  Ubiquitous MyoD transcription at the midblastula transition precedes induction-dependent MyoD expression in presumptive mesoderm of X. laevis.

Authors:  R A Rupp; H Weintraub
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

Review 5.  Synovial lymphocytes and the aetiology of synovitis.

Authors:  H Gaston
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

6.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.

Authors:  G Girasole; R L Jilka; G Passeri; S Boswell; G Boder; D C Williams; S C Manolagas
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

7.  Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

Authors:  D Wendling; E Racadot; J Wijdenes
Journal:  J Rheumatol       Date:  1993-02       Impact factor: 4.666

8.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; P Katsikis; F M Brennan; J Walker; H Bijl; J Ghrayeb
Journal:  Arthritis Rheum       Date:  1993-12

9.  Evidence for the effects of a superantigen in rheumatoid arthritis.

Authors:  X Paliard; S G West; J A Lafferty; J R Clements; J W Kappler; P Marrack; B L Kotzin
Journal:  Science       Date:  1991-07-19       Impact factor: 47.728

10.  Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice.

Authors:  D Brackertz; G F Mitchell; I R Mackay
Journal:  Arthritis Rheum       Date:  1977-04
View more
  117 in total

Review 1.  Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?

Authors:  C Jorgensen; F Apparailly; J Sany
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

2.  Putting the brakes on arthritis: can suppressors of cytokine signaling (SOCS) suppress rheumatoid arthritis?

Authors:  R Rottapel
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 3.  Averting inflammation by targeting the cytokine environment.

Authors:  Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

4.  Osteoblasts and stromal cells isolated from femora in rheumatoid arthritis (RA) and osteoarthritis (OA) patients express IL-11, leukaemia inhibitory factor and oncostatin M.

Authors:  G Lisignoli; A Piacentini; S Toneguzzi; F Grassi; B Cocchini; A Ferruzzi; G Gualtieri; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

5.  Mycoplasma fermentans and TNF-beta interact to amplify immune-modulating cytokines in human lung fibroblasts.

Authors:  James P Fabisiak; Fei Gao; Robyn G Thomson; Robert M Strieter; Simon C Watkins; James H Dauber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-06-02       Impact factor: 5.464

6.  Anti-inflammatory role of IL-17 in experimental autoimmune uveitis.

Authors:  Yan Ke; Ke Liu; Guo-Qiang Huang; Yan Cui; Henry J Kaplan; Hui Shao; Deming Sun
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 7.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

8.  Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease.

Authors:  Hiroaki Ito; Tomonori Hirotani; Mitsunari Yamamoto; Hiroyuki Ogawa; Tadamitsu Kishimoto
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

9.  The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.

Authors:  Jan L Bjersing; Kristina Eriksson; Andrej Tarkowski; L Vincent Collins
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

10.  The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis.

Authors:  Jennifer M McCoy; Joan R Wicks; Laurent P Audoly
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.